Valeant is getting beat up again
Pharmaceutical firm Valeant's stock continued its sell off Monday morning with the stock opening down over 5%.
The stock started falling on September 18, when lawmakers started taking action against companies that gouge the prices of prescription drugs. Since then, it's lost a quarter of its value.
Yahoo Finance
Washington's interest was peaked when the world found out about Martin Shkreli, a hedge fund manager who purchased a prescription drug and jacked up the price 5,000%.
That started a conversation about pharmaceutical firms that engage in the same behavior, and Valeant - a Wall Street darling with a connection to hedge fund manager Bill Ackman - was pinpointed as one of the worst offenders.
Last week, short selling firm Citron research released a note about Valeant with a table listing all the drugs the company purchased and their price increases:
Citron Research
- Global stocks rally even as Sensex, Nifty fall sharply on Friday
- In second consecutive week of decline, forex kitty drops $2.28 bn to $640.33 bn
- SBI Life Q4 profit rises 4% to ₹811 crore
- IMD predicts severe heatwave conditions over East, South Peninsular India for next five days
- COVID lockdown-related school disruptions will continue to worsen students’ exam results into the 2030s: study
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market